A compound represented by Formula (1-I): ** Formula ** or a pharmaceutically acceptable salt thereof, in which: each of D and Z is independently absent or is an optionally substituted linear aliphatic group comprising from zero at eight carbons； each of A and E is independently absent or is a cyclic group； wherein each of said cyclic group is independently selected from the group consisting of aryl, heteroaryl, heterocyclic, C3-C8 cycloalkyl, and C3-C8 cycloalkenyl, each optionally substituted； T is absent or is an optionally substituted aliphatic group； In which one to four of A, D, E, T and Z is absent； Ring B is a five-membered heteroaryl, wherein said heteroaryl is optionally substituted； R1 in each case is independently selected from the group consisting of hydrogen, halogen, cyano, optionally substituted C1-C4 alkyl, -O-R11, -NRaRb, -C (O) R11, -CO2R 11 and -C (O) NRaRb； R11 in each case is independently hydrogen or optionally substituted C1-C8 alkyl； Ra and Rb in each case are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, and optionally substituted C2-C8 alkenyl； or Ra and Rb can be taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic or optionally substituted heteroaryl group； u is independently 1, 2 or 3； Q and J are: R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C3-C8 cycloalkyl； or alternatively, R3 and R4 can be taken together with the carbon atom to which they are attached to form optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclic； R5 in each case is independently hydrogen, optionally substituted C1-C8 alkyl, or optionally substituted C3-C8 cycloalkyl； R6 is selected from the group consisting of -C (O) -R12, -C (O) -C (O) -R12, -S (O) 2-R12 and -C (S) -R12； R12 in each case is i
